Possibilities of use of metformin for correction of endothelial dysfunction and adaptation reserves of an organism in patients with metabolic syndrome

Abstract

Aim. To study possibilities of pharmaceutical correction of clinical laboratory parameters, of endothelial dysfunction and non-specific adaptation reserves in patients with metabolic syndrome (MS) through use of metformin.

Materials and Methods. The three-month program involved 53 patients with MS rando-mized to two comparable groups. Patients of the control group were kept on individual low-calorie diet and practiced graduated exercises. Patients of the studied group, besides the mentioned program of modification of the lifestyle, took metformin. In all participants, anthropometric and clinical laboratory parameters were twice evaluated, total body composition, condition of vascular endothelium and non-specific adaptation reserves of an organism were analyzed. The extent of endothelial dysfunction was evaluated by the level of endothelin-1 and by parameters of photoplethysmographic examination, non-specific adaptation reserves – by the method of analysis of the cardiac rhythm variability.

Results. Metformin in complex with dietary therapy and physical exercises proved to be a safe medical drug for correction of components of MS and of endothelial dysfunction. Use of metformin in patients with MS in combination with dietary therapy and graduated physical exercises as compared to use of the program of modification of the lifestyle alone, leads to reduction in the body mass, waist circumference (in women) and of the total fat mass. Introduction of metformin into the program of complex therapy of patients with MS, provides more evident correction of the parameters of carbohydrate metabolism, reduction of endothelin-1 and stiffness index of the aortic wall, enhancement of parasympathetic regulation, than modification of the lifestyle alone.

Conclusion. Use of metformin in the complex therapy of metabolic syndrome in comparison with the program of modification of the lifestyle, promotes a more significant reduction of the clinical laboratory parameters, of endothelial dysfunction and improves non-specific adaptation reserves of an organism.

Keywords

metabolic syndrome / metformin / endothelial dysfunction / endothelin-1 / cardiac rhythm variability

References

[1] Experts’ consensus on the interdisciplinary approach towards the management, diagnostics, and treatment of patients with metabolic syndrome. Cardiovascular Therapy and Prevention. 2013; 12(6):41-82. (In Russ).

[2] Консенсус Экспертов по междисциплинарному подходу к ведению, диагностике и лечению больных с метаболическим синдромом // Кардиоваскулярная терапия и профилактика. 2013. Т. 6, №12. С. 41-81.

[3] Mamedov MN; Oganov RG, editor. Metaboliches-kiy sindrom v Rossii: rasprostranennost’, klinicheskiye osobennosti i lecheniye. Moscow; 2011. (In Russ).

[4] Мамедов М.Н.; Оганов Р.Г., ред. Метаболический синдром в России: распространенность, клинические особенности и лечение. М.; 2011.

[5] Filatova TE, Nizov AA, Davydov VV. Experience of treatment of male hypertension with obesity, fasting hyperglycemia and deficiency of vitamin D. I.P. Pavlov Russian Medical Biological Herald. 2017;25(1):69-75. (In Russ). doi:10.23888/PAV-LOVJ2017169-75

[6] Филатова Т.Е., Низов А.А., Давыдов В.В. Опыт лечения гипертонической болезни у пациентов мужского пола с ожирением, гипергликемией натощак и дефицитом витамина D // Российский медико-биологический вестник имени академика И.П. Павлова. 2017. Т. 25, №1. С. 69-75. doi:10.23888/PAVLOVJ2017169-75

[7] Yakushin SS, Filippov EV. The main directions of the primary prevention of cardiovascular disease. Eruditio Juvenium. 2014;(4):55-67. (In Russ).

[8] Якушин С.С., Филиппов Е.В. Основные направления первичной профилактики сердечно-сосу-дистых заболеваний // Наука молодых (Eruditio Juvenium). 2014. №4. С. 55-67.

[9] Dashkevich OV, Nizov AA, Lapkin MM, et al. Metabolic syndrome in the practice of the therapist city polyclinic: experience of dietary therapy jam of laminaria, enriched with chromium, and metformin. I.P. Pavlov Russian Medical Biological Herald. 2013;(2):88-92. (In Russ).

[10] Дашкевич О.В., Низов А.А., Лапкин М.М., и др. Метаболический синдром в практике терапевта городской поликлиники: опыт терапии метформином и диетическим продуктом – джемом из морской капусты, обогащенным хромом // Российский медико-биологический вестник имени академика И.П. Павлова. 2013. №2. C. 88-92.

[11] Esler M, Rumantir M, Wiesner G, et al. Sympathetic Nervous System and Insulin Resistance: From Obesity to Diabetes. American Journal of Hypertension. 2001;14(S7):304s-9s. doi:10.1016/s0895-7061 (01)02236-1

[12] Esler M., Rumantir M., Wiesner G., et al. Sympathetic Nervous System and Insulin Resistance: From Obesity to Diabetes // American Journal of Hypertension. 2001. Vol. 14, №S7. P. 304s-309s. doi:10.1016/s0895-7061(01)02236-1

[13] Martynov AI, Avetyak NG, Akatova EV, et al. Endothelial dysfunction and methods for its diagnostics. Russian Journal of Cardiology. 2005;4(54):94-8. (In Russ).

[14] Мартынов А.И., Аветян Н.Г., Акатова Е.В., и др. Эндотелиальная дисфункция и методы её определения // Российский кардиологический журнал. 2005. №4(54). С. 94-98.

[15] Golivets TP, Dubonosova DG, Osipova OA, et al. The effects of endothelin 1 in the development and progression of metabolic syndrome and socially significant non-communicable diseases (review of literature). Scientific Bulletins of Belgorod State University. Series: Medicine. Pharmacia. 2017;19 (268):14-19. (In Russ).

[16] Голивец Т.П., Дубоносова Д.Г., Осипова О.А., и др. Эффекты эндотелина-1 в развитии и прогрессировании метаболического синдрома и других социально значимых неинфекционных заболеваний (обзор литературы) // Научные ведомости БелГУ. Серия: Медицина. Фармация. 2017. №19(268). С. 5-19.

[17] Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovascular Research. 2007;76(1):8-18. doi:10. 1016/j.cardiores.2007.06.004

[18] Bohm F., Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease // Cardiovascular Research. 2007. Vol. 76, №1. P. 8-18. doi:10.1016/j.cardiores.2007.06.004

[19] Verma S, Yao L, Stewart DJ, et al. Endothelin antagonism uncovers insulin-mediated vasorelaxation in vitro and in vivo. Hypertension. 2001;37(2)328-33. doi:10.1161/01.hyp.37.2.328

[20] Verma S., Yao L., Stewart D.J., et al. Endothelin antagonism uncovers insulin-mediated vasorelaxa-tion in vitro and in vivo // Hypertension. 2001. Vol. 37, №2. P. 328-333. doi:10.1161/01.hyp.37.2.328

[21] Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009;120(13):1266-86. doi:10.1161/CIR-CULATIONAHA.108.835223

[22] Xu J., Zou M.H. Molecular insights and therapeutic targets for diabetic endothelial dysfunction // Circulation. 2009. Vol. 120, №13. P. 1266-1286. doi: 10.1161/CIRCULATIONAHA.108.835223

[23] Eriksson L, Nyström T. Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis. Cardiovascular Diabetology. 2014;13(1):152. doi:10.1186/s12933-014-0152-5

[24] Eriksson L., Nyström T. Activation of AMP-activated protein kinase by metformin protects human coronary artery endothelial cells against diabetic lipoapoptosis // Cardiovascular Diabetology. 2014. Vol. 13, №1. P. 152. doi:10.1186/s12933-014-0152-5

[25] Zepeda R, Castillo R, Rodrigo R, et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic & Clinical Pharmacology & Toxicology. 2012;111(5):309-16. doi:10.1111/ j.1742-7843.2012.00911.x

[26] Zepeda R., Castillo R., Rodrigo R., et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension // Basic & Clinical Pharma-cology & Toxicology. 2012. Vol. 111, №5. P. 309-316. doi: 10.1111/j.1742-7843.2012.00911.x

[27] Romantsova TI, Dzhavakhishvili TSh, Roik OV. Effects of metformin on body weight in patients with type 2 diabetes mellitus, receiving insulin analogue treatment. Diabetes Mellitus. 2013;(1):48-51. doi:10.14341/2072-0351-3596

[28] Романцова Т.И., Джавахишвили Т.Ш., Роик О.В. Влияние метформина на массу тела у больных сахарным диабетом 2 типа, получающих аналоги инсулина // Сахарный диабет. 2013. №1. C. 48-51. doi:10.14341/2072-0351-3596

[29] Madiraju AK, Qiu Y, Perry RJ, et al. Author Correction: Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nature Medicine. 2019;25(3):526-8. doi:10.1038/s41591-018-0220-6

[30] Madiraju A.K., Qiu Y., Perry R.J., et al. Author Correction: Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo // Nature Medicine. 2019. Vol. 25, №3. P. 526-528. doi: 10.1038/s41591-018-0220-6

[31] Luo F, Das A, Chen J, et al. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovascular Diabetology. 2019;18(1):54. doi:10.1186/s12933-019-0860-y

[32] Luo F., Das A., Chen J., et al. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management // Cardiovascular Diabetology. 2019. Vol. 18, №1. P. 54. doi: 10.1186/s12933-019-0860-y

[33] Vitale C, Mercuro G, Cornoldi A, et al. Metformin improves endothelial function in patients with me-tabolic syndrome. Journal of Internal Medicine. 2005; 258(3):250-6. doi:10.1111/j.1365-2796.2005. 01531.x

[34] Vitale C., Mercuro G., Cornoldi A., et al. Metformin improves endothelial function in patients with metabolic syndrome // Journal of Internal Medicine. 2005. Vol. 258, №3. P. 250-256. doi:10.1111/ j.1365-2796.2005.01531.x

[35] Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. European Journal of Endocrinology. 2005;152(5):749-56. doi:10.1530/eje.1.0191

[36] Diamanti-Kandarakis E., Alexandraki K., Proto-gerou A., et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome // European Journal of Endocrinology. 2005. Vol. 152, №5. P. 749-756. doi:10.1530/ eje.1.01910

RIGHTS & PERMISSIONS

Nizov A.A., Suchkova E.I., Grivenko A.I., Nikiforova L.V.